Paul Hudson, Sanofi CEO (Jeremy Paoloni/Abaca/Sipa USA(Sipa via AP Images))
February 1, 2024 07:19 AM EST
Pharma
Manufacturing

Due to ‘over­whelm­ing de­mand,’ Sanofi and As­traZeneca’s RSV an­ti­body to be in lim­it­ed sup­ply 

Anna Brown

News Reporter

Sanofi is ex­pect­ing sup­ply con­straints of its in­fant RSV an­ti­body Bey­for­tus, which it co-de­vel­oped with As­traZeneca, in the first quar­ter of this year. While it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times